Gain Therapeutics, Inc.
GANX · XNASCIK 1819411fmd_19SF72M88WF9HM78JYZX80DMNVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | – | – |
| Net interest income | 0 | 0 | 0 | 0 | – | – |
| Research and development | 2 | 7 | 8 | 12 | 11 | 10 |
| Total operating expenses | 4 | 14 | 18 | 22 | 20 | 19 |
| Operating income | (3) | (14) | (18) | (22) | (20) | (19) |
| Interest expense | – | 0 | – | – | – | – |
| Income before taxes | (4) | (14) | (17) | (22) | (20) | (19) |
| Income tax expense | 0 | 0 | 0 | 0 | 1 | 1 |
| Net income from continuing operations | (4) | (14) | (18) | (22) | (20) | (20) |
| Net income | (4) | (14) | (18) | (22) | (20) | (20) |